Park, Seung-HwanSeung-HwanParkZheng, Jin HaiJin HaiZhengNguyen, Vu HongVu HongNguyenJiang, Sheng-NanSheng-NanJiangKim, Dong-YeonDong-YeonKimSzardenings, MichaelMichaelSzardeningsMin, Jung HyunJung HyunMinHong, YeongjinYeongjinHongChoy, Hyon E.Hyon E.ChoyMin, Jung-JoonJung-JoonMin2022-03-052022-03-052016https://publica.fraunhofer.de/handle/publica/24807910.7150/thno.16135Bacteria-based anticancer therapies aim to overcome the limitations of current cancer therapy by actively targeting and efficiently removing cancer. To achieve this goal, new approaches that target and maintain bacterial drugs at sufficient concentrations during the therapeutic window are essential. Here, we examined the tumor tropism of attenuated Salmonella typhimurium displaying the RGD peptide sequence (ACDCRGDCFCG) on the external loop of outer membrane protein A (OmpA). RGD-displaying Salmonella strongly bound to cancer cells overexpressing avv3, but weakly bound to avv3-negative cancer cells, suggesting the feasibility of displaying a preferential homing peptide on the bacterial surface. In vivo studies revealed that RGD-displaying Salmonellae showed strong targeting efficiency, resulting in the regression in avv3-overexpressing cancer xenografts, and prolonged survival of mouse models of human breast cancer (MDA-MB-231) and human melanoma (MDA-MB-435). Thus, surface engineering of Salmonellae to display RGD peptides increases both their targeting efficiency and therapeutic effect.enSalmonella typhimuriumRGD peptidebacteria-mediated cancer therapysurface displaybioluminescence imagingjournal article